◎ Sugi Atlas

Atlas / Drug / Paclitaxel

Paclitaxel

drug
On this page

Also known as (-)-paclitaxelABI-007AbraxaneApealeaApexelsinCapxolCyclopaxDHP 107DHP-107EbetaxelEmpacEndotag 1GenaxolGenetaxylGenexolGenexol-pmIntaxelLep-etuMBT 0206MBT-0206

Summary

Paclitaxel (CHEMBL428647) is an approved small-molecule antineoplastic agent (ATC L01CD01) targeting TLR4, TUBB, and NR1I2; indicated across 169 conditions including breast carcinoma and non-small cell lung carcinoma; with CIViC clinical evidence for 31 variant-indication associations (e.g. ATM Underexpression in stomach cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01CD01
  • Targets: 3 (TLR4, TUBB, NR1I2)
  • Indications: 169 conditions
  • Clinical trials: 2,828
  • Precision-oncology evidence (CIViC): 31 variant–indication associations
  • Chemistry: 853.9 Da · C47H51NO14

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL428647
NamePaclitaxel
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID36314
ChEBICHEBI:45863
ATCL01CD01
Molecular formulaC47H51NO14
Molecular weight853.9
InChIKeyRCINICONZNJXQF-MZXODVADSA-N

SMILES: CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

IUPAC name: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

ChEBI definition: A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name ’taxol’ is now limited, as Taxol is a registered trade mark.

Pharmacological roles (ChEBI): antineoplastic agent, microtubule-stabilising agent.

Other ChEBI roles (chemical / environmental): metabolite, human metabolite.

Also known as: (-)-paclitaxel, ABI-007, Abraxane, Apealea, Apexelsin, Capxol, Cyclopax, DHP 107, DHP-107, Ebetaxel, Empac, Endotag 1

Patent coverage: 91,290 distinct patent families (332,542 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TLR4TLR4Agonist0%O00206
TUBBtubulin beta class IInhibition8.05P07437
NR1I2Pregnane X receptorAgonist5.30.3%O75469

Broader ChEMBL bioactivity targets: 49 (assay-derived). Sample: Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, Nucleotide-binding oligomerization domain-containing protein 2.

Bioactivity

ChEMBL activities: 53 potent at pChembl ≥ 5 of 92 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA8.74Potency1.8nMCHEMBL_ACT_3642846
TUBB38.11IC507.7nMCHEMBL_ACT_13445916
TUBB38.11IC507.7nMCHEMBL_ACT_22484837
TUBB38.04IC509.2nMCHEMBL_ACT_13338835
GMNN7.65Potency22.4nMCHEMBL_ACT_5065095
KDM1A7.53IC5029.6nMCHEMBL_ACT_29080949
TUBB4A7.51EC5031nMCHEMBL_ACT_1677966
ITGB37.47IC5034nMCHEMBL_ACT_1415949
LMNA7.45Potency35.5nMCHEMBL_ACT_3652620
LMNA7.45Potency35.5nMCHEMBL_ACT_4403335
PMP227.32Potency47.8nMCHEMBL_ACT_4358576
LMNA7.2Potency63.1nMCHEMBL_ACT_3667331
RAB9A7.05Potency89.1nMCHEMBL_ACT_3852260
MTOR6.88Potency130.9nMCHEMBL_ACT_3919383
LMNA6.65Potency223.9nMCHEMBL_ACT_3652433
SLCO1B36.58IC50260nMCHEMBL_ACT_15188471
SLCO1B16.55IC50280nMCHEMBL_ACT_15188469
MTOR6.43Potency369nMCHEMBL_ACT_4522710
P025506.28EC50520nMCHEMBL_ACT_12055620
NPC16.25Potency562.3nMCHEMBL_ACT_4721020
THRB6.15Potency707.9nMCHEMBL_ACT_4005743
SLCO1B16.08Ki840nMCHEMBL_ACT_15187569
Q6B8566.08EC50830nMCHEMBL_ACT_457077
P514505.95Potency1122nMCHEMBL_ACT_4991586
TUBB4A5.91EC501230nMCHEMBL_ACT_12623500
CYP3A45.9Potency1259nMCHEMBL_ACT_5005869
CYP3A45.9Potency1259nMCHEMBL_ACT_5070637
CYP3A45.9AC501259nMCHEMBL_ACT_6018661
OPRD15.83Ki1481nMCHEMBL_ACT_7733957
SLCO1B35.75Ki1800nMCHEMBL_ACT_15187556

Target pathways

Aggregated over 3 target gene(s): TLR4, TUBB, NR1I2.

Top Reactome pathways

44 total, by targets touching each:

PathwayTargetsGenes
ER-Phagosome pathway1TLR4
Caspase activation via Death Receptors in the presence of ligand1TLR4
Cell Cycle1TUBB
Disease1TUBB
Toll Like Receptor 4 (TLR4) Cascade1TLR4
MyD88:MAL(TIRAP) cascade initiated on plasma membrane1TLR4
MyD88-independent TLR4 cascade1TLR4
Innate Immune System1TUBB
Immune System1TUBB
Organelle biogenesis and maintenance1TUBB
TRIF-mediated programmed cell death1TLR4
Regulation of PLK1 Activity at G2/M Transition1TUBB
Loss of Nlp from mitotic centrosomes1TUBB
Recruitment of mitotic centrosome proteins and complexes1TUBB
Loss of proteins required for interphase microtubule organization from the centrosome1TUBB
Centrosome maturation1TUBB
Recruitment of NuMA to mitotic centrosomes1TUBB
Nuclear Receptor transcription pathway1NR1I2
SUMOylation of intracellular receptors1NR1I2
Mitotic G2-G2/M phases1TUBB
MyD88 deficiency (TLR2/4)1TLR4
IRAK4 deficiency (TLR2/4)1TLR4
Cilium Assembly1TUBB
Anchoring of the basal body to the plasma membrane1TUBB
Infectious disease1TUBB
Regulation of TLR by endogenous ligand1TLR4
Neutrophil degranulation1TUBB
Mitotic Prometaphase1TUBB
M Phase1TUBB
G2/M Transition1TUBB

Dominant GO biological processes

GO termTargets
gene expression2
positive regulation of gene expression2
positive regulation of transcription by RNA polymerase II2
intestinal epithelial structure maintenance2
signal transduction2
toll-like receptor signaling pathway1
wound healing involved in inflammatory response1
B cell proliferation involved in immune response1
nitric oxide production involved in inflammatory response1
regulation of dendritic cell cytokine production1
MyD88-dependent toll-like receptor signaling pathway1
growth plate cartilage morphogenesis1
nitric oxide biosynthetic process1
phagocytosis1
inflammatory response1

Indications & clinical

Indications

169 indications (16 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast carcinoma4MONDO:0004989EFO:0000305
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
neoplasm4MONDO:0005070EFO:0000616
ovarian carcinoma4MONDO:0005140EFO:0001075
Kaposi’s sarcoma4MONDO:0005055EFO:0000558
exocrine pancreatic carcinoma4MONDO:0005192EFO:0002618
breast neoplasm4MONDO:0021100EFO:0003869
pancreatic neoplasm4MONDO:0021040EFO:0003860
carcinoma4MONDO:0004993EFO:0000313
ovarian neoplasm4MONDO:0021068EFO:0003893
undifferentiated carcinoma4MONDO:0005617EFO:0006772
ovarian cancer4MONDO:0008170MONDO:0008170
HER2 positive breast carcinoma4MONDO:0006244EFO:1000294
malignant pancreatic neoplasm4MONDO:0009831EFO:1000359
gastric adenocarcinoma3MONDO:0005036EFO:0000503
gastric carcinoma3MONDO:0004950EFO:0000178
melanoma3MONDO:0005105EFO:0000756
metastatic melanoma3MONDO:0005191EFO:0002617
cervical carcinoma3MONDO:0005131EFO:0001061
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
squamous cell carcinoma3MONDO:0005096EFO:0000707
carcinoma of esophagus3MONDO:0019086EFO:0002916
tumor of uterus3MONDO:0021353EFO:0003859
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
male breast carcinoma3MONDO:0005628EFO:0006861
cutaneous melanoma3MONDO:0005012EFO:0000389
endometrium neoplasm3MONDO:0021251EFO:0004230
peritoneal neoplasm3MONDO:0006901EFO:1001100
sarcoma3MONDO:0005089EFO:0000691
peripheral arterial disease3MONDO:0005386EFO:0004265
HIV infectious disease3MONDO:0005109EFO:0000180
adenocarcinoma3MONDO:0004970EFO:0000228
urinary bladder neoplasm3MONDO:0004987EFO:0000294
ischemic disease3MONDO:0005053EFO:0000556
cervical adenocarcinoma3MONDO:0005153EFO:0001416
lung large cell carcinoma3MONDO:0003050EFO:0003050
gastric neoplasm3MONDO:0021085EFO:0003897
nasopharyngeal neoplasm3MONDO:0005375EFO:0004252
testicular cancer3MONDO:0005447EFO:0004281
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
head and neck cancer3MONDO:0005627EFO:0006859
fallopian tube carcinoma3MONDO:0006206EFO:1000251
inflammatory breast carcinoma3MONDO:0006804EFO:1000984
female reproductive organ cancer3MONDO:0001416EFO:1001331
endometrial carcinoma3MONDO:0002447EFO:1001512
soft tissue sarcoma3MONDO:0018078EFO:1001968
lung adenocarcinoma3MONDO:0005061EFO:0000571
peripheral neuropathy3MONDO:0005244EFO:0003100
urothelial carcinoma3MONDO:0040679EFO:0008528
uterine carcinosarcoma3MONDO:0006485EFO:1000613
peripheral nervous system disorder3MONDO:0003620EFO:0004149
fallopian tube neoplasm3MONDO:0021092MONDO:0002158
teratoma3MONDO:0002601MONDO:0002601
uterine cancer3MONDO:0002715MONDO:0002715
lung neoplasm3MONDO:0021117MONDO:0008903
oral cavity squamous cell carcinoma3MONDO:0004958EFO:0000199
anemia3MONDO:0002280EFO:0004272
laryngeal squamous cell carcinoma3MONDO:0005595EFO:0006352
thyroid gland carcinoma3MONDO:0015075EFO:0002892
female reproductive system neoplasm3MONDO:0021148MONDO:0021148
allergic disease3MONDO:0005271MONDO:0005271
uterine corpus cancer3MONDO:0006003EFO:0007532
sex cord-stromal tumor3MONDO:0006055EFO:1000052
paraganglioma3MONDO:0000448EFO:1000453
pancreatic ductal adenocarcinoma3MONDO:0005184MONDO:0005184
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
small cell lung carcinoma2MONDO:0008433EFO:0000702
plasma cell myeloma2MONDO:0009693EFO:0001378
peripheral vascular disease2MONDO:0005294EFO:0003875
hepatocellular carcinoma2MONDO:0007256EFO:0000182
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
benign prostatic hyperplasia2MONDO:0010811EFO:0000284
minimally invasive lung adenocarcinoma2MONDO:0004991EFO:0000308
germ cell tumor2MONDO:0005040EFO:0000514
leukemia2MONDO:0005059EFO:0000565
lymphoma2MONDO:0005062EFO:0000574
prostate adenocarcinoma2MONDO:0005082EFO:0000673
psoriasis2MONDO:0005083EFO:0000676
rheumatoid arthritis2MONDO:0008383EFO:0000685
actinic keratosis2MONDO:0005173EFO:0002496
oral cavity neoplasm2MONDO:0021245EFO:0003868
angiosarcoma2MONDO:0016982EFO:0003968
cholangiocarcinoma2MONDO:0019087EFO:0005221
hereditary breast ovarian cancer syndrome2MONDO:0003582Orphanet:145
endometrioid adenocarcinoma2MONDO:0005026EFO:0000466
colorectal neoplasm2MONDO:0005335EFO:0004142
thymic carcinoma2MONDO:0006451EFO:1000576
thymoma2MONDO:0006456EFO:1000581
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
oropharynx cancer2MONDO:0004608EFO:1001931
intrahepatic cholangiocarcinoma2MONDO:0003210EFO:1001961
hypopharyngeal carcinoma2MONDO:0005216EFO:0002938
breast ductal adenocarcinoma2MONDO:0005590EFO:0006318
ovarian serous cystadenocarcinoma2MONDO:0006046EFO:1000043
central nervous system neoplasm2MONDO:0006130EFO:1000158
penile neoplasm2MONDO:0006895MONDO:0001325
vulva cancer2MONDO:0001528MONDO:0001528
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
kidney cancer2MONDO:0002367MONDO:0002367
breast carcinoma in situ2MONDO:0004658MONDO:0004658
salivary gland cancer2MONDO:0004669MONDO:0004669
gallbladder neoplasm2MONDO:0021253MONDO:0005411
bone cancer2MONDO:0002129EFO:1000350
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
mixed neoplasm2MONDO:0021043MONDO:0021043
glioma2MONDO:0021042MONDO:0100342
dysplasia of cervix2MONDO:0006736MONDO:0022394
vulvar carcinoma2MONDO:0005215EFO:0002921
bone neoplasm2MONDO:0019060EFO:0003820
ocular melanoma2MONDO:0006325EFO:1000403
uveal melanoma2MONDO:0006486EFO:1000616
coronary restenosis1MONDO:0005355EFO:0004224
glioblastoma1MONDO:0018177EFO:0000519
Hodgkins lymphoma1MONDO:0004952EFO:0000183
mesothelioma1MONDO:0005065EFO:0000588
renal cell carcinoma1MONDO:0005086EFO:0000681
verrucous carcinoma1MONDO:0006006EFO:0007535
rectal cancer1MONDO:0006519EFO:1000657
small cell carcinoma1MONDO:0000402EFO:0008524
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
vaginal cancer1MONDO:0001402MONDO:0001402
anus neoplasm1MONDO:0003046MONDO:0001879
gliosarcoma1MONDO:0016681EFO:1001465
ductal breast carcinoma in situ1MONDO:0005023EFO:0000432
brain neoplasm1MONDO:0021211EFO:0003833
carcinoid tumor1MONDO:0005369EFO:0004243
malignant peritoneal mesothelioma1MONDO:0005512EFO:0005567
cystic, mucinous, and serous neoplasm1MONDO:0006720MONDO:0037256
thyroid gland undifferentiated (anaplastic) carcinoma0MONDO:0006468EFO:1000595

36 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,828.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,828 total).

PhaseTrials
PHASE2757
PHASE3601
PHASE1/PHASE2148
PHASE2/PHASE365
PHASE429

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03096418PHASE4RECRUITINGNeoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT05035147PHASE4RECRUITINGAlbumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
NCT05183126PHASE4RECRUITINGPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT00418067PHASE4COMPLETEDZotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions
NCT00422565PHASE4TERMINATEDZotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients
NCT00606515PHASE4COMPLETEDPharmacokinetics Study of Liposomal Paclitaxel in Humans
NCT00852215PHASE4UNKNOWNDo Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion?
NCT00987324PHASE4COMPLETEDEfficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis
NCT01066832PHASE4COMPLETEDThe Valentines Trial
NCT01078051PHASE4TERMINATEDDrug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)
NCT01094184PHASE4COMPLETEDA Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
NCT01156961PHASE4WITHDRAWNA Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
NCT01301729PHASE4COMPLETEDA Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01317615PHASE4COMPLETEDRAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
NCT01706120PHASE4UNKNOWNStudy of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01994031PHASE4UNKNOWNDose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
NCT02207361PHASE4UNKNOWNPaclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
NCT02419742PHASE4COMPLETEDSafety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
NCT02513355PHASE4UNKNOWNEndostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
NCT02996214PHASE4UNKNOWNPaclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)
NCT03092986PHASE4COMPLETEDOutcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03794778PHASE4UNKNOWNEvaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
NCT04217096PHASE4UNKNOWNEfficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
NCT04489888PHASE4COMPLETEDA Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
NCT04766827PHASE4UNKNOWNAlbumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor
NCT05033769PHASE4UNKNOWNAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
NCT05291910PHASE4UNKNOWNInetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
NCT05603065PHASE4UNKNOWNTislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
NCT05730777PHASE4UNKNOWNCorrelation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
NCT00070564PHASE3ACTIVE_NOT_RECRUITINGS0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00433420PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
NCT00433511PHASE3ACTIVE_NOT_RECRUITINGDoxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
NCT00565851PHASE3ACTIVE_NOT_RECRUITINGCarboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT01057069PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNeo Adjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01081262PHASE3ACTIVE_NOT_RECRUITINGCarboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01167712PHASE3ACTIVE_NOT_RECRUITINGPaclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01566240PHASE3ACTIVE_NOT_RECRUITINGInduction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT01646034PHASE3ACTIVE_NOT_RECRUITINGHigh Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
NCT01820858PHASE3ACTIVE_NOT_RECRUITINGThe Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
NCT02135042PHASE2/PHASE3ACTIVE_NOT_RECRUITINGIndividualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Clinical evidence (CIViC)

Variant × indication × effect (31 predictive associations from 32 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
ATM UnderexpressionStomach CancerSensitivity/ResponsePaclitaxel + OlaparibCIViC BEID5215 +1
ABCB1 S893TOvarian CancerSensitivity/ResponsePaclitaxelCIViC BEID674
CCND1 AmplificationSkin MelanomaSensitivity/ResponseSorafenib + Carboplatin + PaclitaxelCIViC BEID1495
EMSY OverexpressionOvarian Serous CarcinomaSensitivity/ResponsePaclitaxel + Bevacizumab + CarboplatinCIViC BEID12149
ERBB2 OverexpressionEndometrial Serous AdenocarcinomaSensitivity/ResponseCarboplatin + Paclitaxel + TrastuzumabCIViC BEID7386
ERCC2 K751QLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + CarboplatinCIViC BEID677
ETS2 RS461155Lung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + CisplatinCIViC BEID1060
MSI HighEndometrial CancerSensitivity/ResponseCarboplatin + Dostarlimab + PaclitaxelCIViC BEID12341
MSI HighEndometrial CancerSensitivity/ResponsePaclitaxel + Dostarlimab + CarboplatinCIViC BEID12343
PDCD4 EXPRESSIONLung CancerSensitivity/ResponsePaclitaxelCIViC BEID821
PTEN LossSolid TumorSensitivity/ResponseBuparlisib + Carboplatin + PaclitaxelCIViC BEID5957
RAF1 AmplificationSkin MelanomaSensitivity/ResponsePaclitaxel + Sorafenib + CarboplatinCIViC BEID1496
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + Gemcitabine + CisplatinCIViC BEID12044
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + Vinorelbine + GemcitabineCIViC BEID5599
KRAS RS61764370Epithelial Ovarian CancerResistancePaclitaxel + CarboplatinCIViC BEID664
STMN1 EXPRESSIONEndometrial CarcinomaResistancePaclitaxelCIViC BEID855
TIMP1 OverexpressionBreast CancerResistancePaclitaxelCIViC BEID927
ERCC1 ExpressionBladder CarcinomaPaclitaxel + Cisplatin + GemcitabineCIViC BEID6438
ERBB2 OverexpressionSalivary Gland CancerSensitivity/ResponsePaclitaxel + TrastuzumabCIViC CEID6170
PTEN LossCancerSensitivity/ResponseCarboplatin + Buparlisib + PaclitaxelCIViC CEID714
GSTP1 DeletionOvarian CarcinomaSensitivity/ResponseCarboplatin + Paclitaxel + CisplatinCIViC DEID660
NRG1 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + Gemcitabine + Carboplatin + PaclitaxelCIViC DEID779
ABCB1 OverexpressionLung Non-small Cell CarcinomaResistancePaclitaxelCIViC DEID944
ABCC10 OverexpressionLung Non-small Cell CarcinomaResistancePaclitaxelCIViC DEID952
ABCC3 AmplificationBreast CancerResistanceMonomethyl Auristatin E + PaclitaxelCIViC DEID951
ASS1 LossOvarian CancerResistanceTaxol + Carboplatin + CisplatinCIViC DEID5989
AURKA OverexpressionCervical AdenocarcinomaResistancePaclitaxelCIViC DEID457
MYD88 OverexpressionBreast CancerResistancePaclitaxelCIViC DEID734
SYK OVEREXPRESSIONOvarian CancerResistancePaclitaxelCIViC DEID752
TP53 R248QOvarian CancerResistancePaclitaxel + Doxorubicin + EtoposideCIViC DEID7175

+1 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

GuidelineSourceGene(s)DosingRecommendation
Annotation of DPWG Guideline for paclitaxel and CYP3A4DPWGCYP3A4

PharmGKB also curates 45 clinical and 242 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

298 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CARVEDILOLChEMBL + PubChemPhase 4 (approved)NR1I2, TLR4
METHOTREXATEChEMBL + PubChemPhase 4 (approved)NR1I2, TLR4
PATUPILONEChEMBLPhase 3NR1I2, TUBB
BOSENTANChEMBL + PubChemPhase 4 (approved)NR1I2
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)NR1I2
DACOMITINIBChEMBL + PubChemPhase 4 (approved)NR1I2
DESOXYCORTICOSTERONE PIVALATEChEMBL + PubChemPhase 4 (approved)NR1I2
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR1I2
GEFITINIBChEMBL + PubChemPhase 4 (approved)NR1I2
PODOFILOXChEMBL + PubChemPhase 4 (approved)TUBB
TADALAFILChEMBL + PubChemPhase 4 (approved)NR1I2
VINBLASTINEChEMBL + PubChemPhase 4 (approved)TUBB
ABACAVIRChEMBLPhase 4 (approved)NR1I2
ACENOCOUMAROLChEMBLPhase 4 (approved)NR1I2
ACETAMINOPHENChEMBLPhase 4 (approved)NR1I2
ACITRETINChEMBLPhase 4 (approved)NR1I2
ADAPALENEChEMBLPhase 4 (approved)NR1I2
ALECTINIBChEMBLPhase 4 (approved)NR1I2
ALPIDEMChEMBLPhase 4 (approved)NR1I2
AMBRISENTANChEMBLPhase 4 (approved)NR1I2
AMLODIPINEChEMBLPhase 4 (approved)NR1I2
AMSACRINEChEMBLPhase 4 (approved)NR1I2
ATAZANAVIRChEMBLPhase 4 (approved)NR1I2
ATORVASTATINChEMBLPhase 4 (approved)NR1I2
BEDAQUILINEChEMBLPhase 4 (approved)NR1I2
BENFLUOREXChEMBLPhase 4 (approved)NR1I2
BENZBROMARONEChEMBLPhase 4 (approved)NR1I2
BENZTHIAZIDEChEMBLPhase 4 (approved)NR1I2
BEPRIDILChEMBLPhase 4 (approved)NR1I2
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR1I2
BIFONAZOLEChEMBLPhase 4 (approved)NR1I2
BITHIONOLChEMBLPhase 4 (approved)NR1I2
BRIMONIDINEChEMBLPhase 4 (approved)NR1I2
BROMPERIDOLChEMBLPhase 4 (approved)NR1I2
BUCLIZINEChEMBLPhase 4 (approved)NR1I2
BUTENAFINEChEMBLPhase 4 (approved)NR1I2
BUTOCONAZOLEChEMBLPhase 4 (approved)NR1I2
CALCIPOTRIENEChEMBLPhase 4 (approved)NR1I2
CALCITRIOLChEMBLPhase 4 (approved)NR1I2
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR1I2
CANNABIDIOLChEMBLPhase 4 (approved)NR1I2
CAPSAICINChEMBLPhase 4 (approved)NR1I2
CEFACLORChEMBLPhase 4 (approved)NR1I2
CEFAMANDOLEChEMBLPhase 4 (approved)NR1I2
CEFEPIMEChEMBLPhase 4 (approved)NR1I2
CEFMENOXIMEChEMBLPhase 4 (approved)NR1I2
CEFOTAXIMEChEMBLPhase 4 (approved)NR1I2
CEFOXITINChEMBLPhase 4 (approved)NR1I2
CEFPODOXIMEChEMBLPhase 4 (approved)NR1I2
CEFTAZIDIMEChEMBLPhase 4 (approved)NR1I2
CEFTIZOXIMEChEMBLPhase 4 (approved)NR1I2
CEFTRIAXONEChEMBLPhase 4 (approved)NR1I2
CEFUROXIMEChEMBLPhase 4 (approved)NR1I2
CEPHALORIDINEChEMBLPhase 4 (approved)NR1I2
CEPHALOTHINChEMBLPhase 4 (approved)NR1I2
CEPHAPIRINChEMBLPhase 4 (approved)NR1I2
CEPHRADINEChEMBLPhase 4 (approved)NR1I2
CHLORHEXIDINEChEMBLPhase 4 (approved)NR1I2
CHLOROXINEChEMBLPhase 4 (approved)NR1I2
CHLORPROTHIXENEChEMBLPhase 4 (approved)NR1I2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot